EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)

被引：0
|
作者：
Enrico, A. [1 ]
Milone, J. [1 ]
Moiraghi, B. [2 ]
Casanova, L. [3 ,4 ]
Undurraga, M. S. [5 ]
Olivera, L. Enciso [6 ,7 ]
Bullorsky, E. [8 ]
Navarro Cabrera, J. [9 ]
Pagnano, K. [10 ]
De Riz, M. [11 ]
Pavlovsky, C. [12 ]
机构：
[1] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina
[2] Hosp JM Ramos Mejia, Caba, Argentina
[3] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru
[4] Clin Oncol Miraflores, Dept Med Oncol, Lima, Peru
[5] Hosp Salvador, Santiago, Chile
[6] Inst Nacl Cancerol Bogota, Bogota, Colombia
[7] Univ Nacl Colombia, Bogota, Colombia
[8] Hosp Britanico Buenos Aires, Caba, Argentina
[9] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[10] Univ Estadual Campinas, Hemoctr Unicamp, Campinas, SP, Brazil
[11] Bristol Myers Squibb, Dept Med, Buenos Aires, DF, Argentina
[12] FUNDALEU, Caba, Argentina
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1119
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [31] Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
    Shah, Neil P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Bilmes, Robyn
    Li, Li
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
    Kantarjian, Hagop
    Shah, Neil P.
    Hochhaus, Andreas
    Cortes, Jorge
    Shah, Sandip
    Ayala, Manuel
    Moiraghi, Beatriz
    Shen, Zhixiang
    Mayer, Jiri
    Pasquini, Ricardo
    Nakamae, Hirohisa
    Huguet, Francoise
    Boque, Concepcion
    Chuah, Charles
    Bleickardt, Eric
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Szatrowski, Ted
    Shapiro, David
    Baccarani, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
  • [33] MOLECULAR RESPONSE KINETICS AND BCR-ABL REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) RECEIVING DASATINIB VS IMATINIB: DASISION 3-YEAR FOLLOW-UP
    Hochhaus, A.
    Boque, C.
    Bradley Garelik, M.
    Manos, G.
    Steegmann, J. L.
    HAEMATOLOGICA, 2012, 97 : 76 - 76
  • [34] Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter in China
    Yu, Wenjuan
    Du, Xin
    Wang, Weiguang
    Lou, Jin
    Liu, Peng
    Meng, Li
    Jin, Jie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : E867 - E873
  • [35] Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
    Kantarjian, Hagop M.
    Shah, Neil P.
    Cortes, Jorge E.
    Baccarani, Michele
    Agarwal, Mohan B.
    Soledad Undurraga, Maria
    Wang, Jianxiang
    Kassack Ipina, Juan Julio
    Kim, Dong-Wook
    Ogura, Michinori
    Pavlovsky, Carolina
    Junghanss, Christian
    Milone, Jorge H.
    Nicolini, Franck E.
    Robak, Tadeusz
    Van Droogenbroeck, Jan
    Vellenga, Edo
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Hochhaus, Andreas
    BLOOD, 2012, 119 (05) : 1123 - 1129
  • [36] Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report
    Nakamae, Hirohisa
    Fujisawa, Shin
    Ogura, Michinori
    Uchida, Toshiki
    Onishi, Yasushi
    Taniwaki, Masafumi
    Utsunomiya, Atae
    Matsue, Kosei
    Takamatsu, Yasushi
    Usuki, Kensuke
    Tanimoto, Mitsune
    Ishida, Yoji
    Ohashi, Kazuteru
    Li, Li
    Miyoshi, Masafumi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (06) : 792 - 804
  • [37] Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report
    Hirohisa Nakamae
    Shin Fujisawa
    Michinori Ogura
    Toshiki Uchida
    Yasushi Onishi
    Masafumi Taniwaki
    Atae Utsunomiya
    Kosei Matsue
    Yasushi Takamatsu
    Kensuke Usuki
    Mitsune Tanimoto
    Yoji Ishida
    Kazuteru Ohashi
    Li Li
    Masafumi Miyoshi
    International Journal of Hematology, 2017, 105 : 792 - 804
  • [38] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [39] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Deininger, Michael W.
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Guilhot, Francois
    BLOOD, 2013, 122 (21)
  • [40] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
12345